http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-102216725-B1
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-52 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5088 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5011 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-50 |
| filingDate | 2018-12-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2021-02-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2021-02-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-102216725-B1 |
| titleOfInvention | Method for prediction of response to cancer immunotherapy |
| abstract | In the present specification, for a biological sample isolated from an individual after immuno-anticancer therapy is performed, MDSC from monocytes, MDSC from polymorphnuclear, and lectin-type oxidized LDL receptor-1 (Lox-1) positive polymorphic nucleus. Measuring the level of at least one marker selected from the group consisting of MDSC, T reg cells, CD8 + T cells, CD4 + T cells, NK cells and B cells, and immuno-anti-cancer for the subject based on the level of the measured marker. A method of predicting a treatment response to an immune anticancer therapy is provided, comprising the step of evaluating the treatment response of the therapy. |
| priorityDate | 2017-12-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 25.